Dr. Jennifer Levin Carter, founder and CEO of Medzown, discusses what makes precision medicine different from personalized medicine and what how challenges faced in this evolving field can be overcome.

Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, spoke with PharmTech about the company’s immune-directed antibody-drug conjugate (ADC) strategy, the benefits of VISTA-targeted ADCs in drug delivery, and Lifordi’s plans at the JP Morgan Healthcare Conference.

Beena Wood, Qinecsa, saw 2025 as an AI superposition in which pharmacovigilence needed better data foundations and regulation.

Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

The company’s new AI agent automates labor-intensive processes involved in trial document management.

In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and evolving drug development landscape.

Mike Stenberg, LGM Pharma, explains how faster FDA approvals under CNPV shift bottlenecks to production, requiring onshoring and earlier supply chain risk.

The move brings Amgen first-in-class, small molecule-targeted protein degraders for oncology.

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.

Raj Puri, chief commercial officer at Argonaut Manufacturing, talks about how navigating the pressure to respond to tariffs with investments and keeping a robust and qualified staff are key moves in the new year.

Meri Beckwith, Co-CEO of Lindus Health, provides a look at how trends that developed in 2025 will impact the pharmaceutical industry in 2026.

China clears GSK’s Nucala (mepolizumab) for COPD, highlighting growing acceptance in the country for biomarker-driven therapies.

Saharsh Davuluri, Neuland Labs, discusses the move from labor to knowledge arbitrage for API manufacturers, using AI tools to empower scientists in process development.

This paper provides a technical assessment of compendial tests commonly found in the European Pharmacopoeia, the United States Pharmacopeia–National Formulary, and the Japanese Pharmacopoeia, detailing differences between the methods and acceptance criteria, and the potential impact of these differences on multi-compendial compliance.

FUJIFILM Irvine Scientific has changed its name to FUJIFILM Biosciences to better align with the company’s work in cell culture media manufacturing.

Remco Munnik, Arcana, details pharma's shift to data-first operations, AI adoption, and robust data stewardship.

Saharsh Davuluri, Neuland Labs, covers M&A blending, geopolitical shifts, and supply chain de-risking in this look back at pharma in 2025.

PharmTech spoke with Ian Bilodeau, managing director, Ardena US about how the expanded use of AI has impacted the pharmaceutical industry and the importance of nurturing top talent for a robust workforce.

Manish Garg, Hikma, reflects on how AI, resilient supply chains, and smart manufacturing are reshaping pharma today and beyond.

ROSS’s DCB-5 Double Cone Tumble Blender can handle high-density materials and provides repeatable homogeneity and powder blending properties, according to the company.

In the concluding segment of a multi-part interview, Jason Bryant of ArisGlobal explains how human-in-the-loop and human-on-the-loop are both still relevant in AI implementation in pharma.

Felix Gonzalez, FounderNest, offers a data-driven view of where pharma consolidation is occurring, where capital is being deployed, and how regional M&A strategies differ.

2025 pharma disruption hinged on three themes: political pricing/tariffs, tough quality scrutiny (FDA warnings), and innovation vs. changing standards (patient focus.

PharmTech spoke with Campbell Bunce, chief scientific officer, Abzena to find out which trends in 2025 impacted the industry the most.

ArisGlobal’s Jason Bryant continues a video supplement to his series of articles on the adoption and implementation of AI agents.

In this overview, PharmTech takes a look back at significant news in the development and approval of cancer treatment in 2025.

Henrik Johanning, Epista Life Sciences, takes a European perspective on what will be required of pharma developers and manufacturers in 2026.